Phibro Anl Htlh A (PAHC) |
|
21.32 -0.03 (-0.14%)
|
01-27 01:27 |
|
Open: |
21.6 |
Pre. Close: |
21.35 |
|
High:
|
21.6967 |
Low:
|
21.16 |
|
Volume:
|
86,813 |
Market Cap:
|
862M |
|
|
|
|
Phibro Animal Health Corporation develops, manufactures, and supplies a range of animal health and mineral nutrition products for livestock primarily in the United States. It operates through three segments: Animal Health, Mineral Nutrition, and Performance Products. The company develops, manufactures, and markets products for a range of food animals, including poultry, swine, beef and dairy cattle, and aquaculture. Its animal health products also comprise antibacterials that are biological or chemical products used in the animal health industry to treat or to prevent bacterial diseases; anticoccidials primarily used to prevent and control the disease coccidiosis in poultry and cattle; anthelmintics to treat infestations of parasitic intestinal worms; and anti-bloat treatment products for cattle to control bloat in animals grazing on legume or wheat-pasture. In addition, the company offers nutritional specialty products, which enhance nutrition to help improve health and performance; and vaccines to prevent diseases primarily for the poultry and swine markets. Further, it manufactures and markets formulations and concentrations of trace minerals, such as zinc, manganese, copper, iron, and other compounds; and various specialty ingredients for use in the personal care, industrial chemical, and chemical catalyst industries. The company sells its animal health and mineral nutrition products through local sales offices to integrated poultry, swine, and cattle integrators, as well as through commercial animal feed manufacturers, wholesalers, and distributors. It also operates in Latin America, Canada, Europe, the Middle East, Africa, and the Asia Pacific. The company was formerly known as Philipp Brothers Chemicals, Inc. and changed its name to Phibro Animal Health Corporation in July 2003. Phibro Animal Health Corporation was incorporated in 2014 and is headquartered in Teaneck, New Jersey. |
Stock Price Prediction |
Update at 5:00pm EST |
|
If tomorrow:
|
Open lower
|
Open higher
|
|
High:
|
21.732 - 21.841 |
21.841 - 21.932 |
|
Low:
|
20.908 - 21.024 |
21.024 - 21.118 |
|
Close:
|
21.141 - 21.322 |
21.322 - 21.47 |
|
Technical analysis |
as of: 2021-01-26 4:47:26 PM |
|
Overall:
|
 |
| Stoxline posted a NEUTRAL today, same as yesterday. Current trend continues, but could change at anytime. It is not a good time to buy or sell. |
| Target: |
Six months: 25.34  One year: 29.60 |
| Support: |
Support1: 19.82 Support2: 18.66 |
| Resistance: |
Resistance1: 21.70 Resistance2: 25.34 |
| Pivot: |
21.07 |
| Moving Average: |
MA(5): 21.30 MA(20): 20.62
MA(100): 18.78 MA(250): 21.90  |
| MACD: |
MACD(12,26): 0.60 Signal(9): 0.60 |
| Stochastic oscillator: |
%K(14,3): 86.13 %D(3): 87.27 |
| RSI: |
RSI(14): 67.99 |
| 52-week: |
High: 29.38 Low: 16.27 Change(%): -15.9 |
| Average Vol(K): |
3-Month: 15389 10-Days: 12342 |
|
Price, moving averages and Bollinger Bands |
|
Price and moving averages has closed above its Short term moving average. Short term moving average is currently above mid-term; AND above long term moving averages. From the relationship between price and moving averages; we can see that: This stock is BULLISH in short-term; and BULLISH in mid-long term.PAHC has closed below upper band by 35.0%. Bollinger Bands are 34.2% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices. |
|
|
Headline News |
Mon, 06 May 2019
Phibro Animal Health Corporation Declares Quarterly Dividend - GlobeNewswire
Wed, 05 Jul 2017
Phibro Animal Health Corporation and Zydus Cadila announce their intention to license Phibro's Poultry Vaccine Technologies - GlobeNewswire
Tue, 12 Jan 2016
Phibro Animal Health Corporation to Acquire Business of MVP Laboratories, Inc., an Animal Vaccine and Adjuvant Manufacturer and Marketer - GlobeNewswire
Wed, 31 Dec 1969
Wed, 31 Dec 1969
Wed, 31 Dec 1969
|
Financial Analysis |
| Growth |
|
| Growth measures the growth of both a company's revenue and net income. it tells investors how fast a company is growing. |
| Profitability |
 |
| Profitability measures a company’s ability to generate earnings as compared to its expenses and other relevant costs. |
| Solvency |
 |
| Solvency measures a company's ability to meet its long-term debts. Acceptable solvency ratios will vary from industry to industry. |
| Efficiency |
|
| Efficiency measures the strength of a company's return on invested capital. It can identify business that are better managed or not. |
| Price to Book Value: |
Outperform |
Discounted cash flow: |
Outperform |
| Return on Assets: |
Neutral |
Price to Earnings: |
Outperform |
| Return on Equity: |
Neutral |
Debt to Equity: |
Outperform |
|
|
|
|
|
|
| Free Technical Analysis Charts
|
|
|
Stock Basics & Statistics |
| Exchange: NASDAQ |
| Sector: Healthcare |
| Industry: Drug Manufacturers General Specialty & Generic |
| Shares Out. (M) |
20 |
| Shares Float (M) |
20 |
|
% Held by Insiders
|
0.40 |
|
% Held by Institutions
|
108.51 |
|
Shares Short (K)
|
950 |
|
Shares Short P. Month (K)
|
1,000 |
Stock Financials |
|
EPS
|
1.070 |
|
EPS Est This Year
|
1.560 |
|
EPS Est Next Year
|
1.690 |
|
Book Value (p.s.)
|
4.760 |
|
Profit Margin
|
5.38 |
|
Operating Margin
|
8.92 |
|
Return on Assets (ttm)
|
5.7 |
|
Return on Equity (ttm)
|
21.7 |
|
Qtrly Rev. Growth
|
2.9 |
|
Gross Profit (p.s.)
|
12.674 |
|
Sales Per Share
|
39.716 |
|
EBITDA (p.s.)
|
5.100 |
|
Qtrly Earnings Growth
|
389.10 |
|
Operating Cash Flow (M)
|
65 |
|
Levered Free Cash Flow (M)
|
52 |
Stock Valuations |
|
PE Ratio
|
19.92 |
|
PEG Ratio
|
1.81 |
|
Price to Book value
|
4.48 |
|
Price to Sales
|
0.54 |
|
Price to Cash Flow
|
6.69 |
Stock Dividends |
|
Dividend
|
0.480 |
|
Forward Dividend
|
0.480 |
|
Dividend Yield
|
0.02 |
|
Dividend Pay Date
|
2020-12-15 |
|
Ex-Dividend Date
|
2020-11-23 |
|
7 Binary Options
|
|
Your Ad Here
|
|
